Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00122447 · ClinicalTrials.gov registry record · NA
Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 84
- Enrollment target
NCT00122447 is a NA study that has completed, run by Emory University. The registered enrollment target is 84 participants.
The verdict
NCT00122447, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.
Interventions
- DRUG Placebo
- DRUG Aspirin
- DRUG Olmesartan
- DRUG Alpha lipoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2005-05 |
| Est. Completion | 2011-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00122447
The ClinicalTrials.gov registry entry for NCT00122447 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00122447 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00122447 about?
NCT00122447 is a clinical study titled "Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance". The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in ...
What is the current status of trial NCT00122447?
This trial is currently completed. It is a NA study. The enrollment target is 84 participants. The study started on 2005-05. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00122447?
The interventions under investigation include: Placebo (DRUG), Aspirin (DRUG), Olmesartan (DRUG), Alpha lipoic acid (DRUG).
Who is sponsoring clinical trial NCT00122447?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.